Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia
Abstract
Despite advances in the treatment of acute myeloid leukemia (AML), novel therapies are needed to induce deeper and more durable clinical response. Bispecific T-cell Engager (BiTE) molecules, which redirect patient T cells to lyse tumor cells, are a clinically validated modality for hematologic malignancies. Due to broad AML expression and limited normal tissue expression, fms-related tyrosine kinase 3 (FLT3) is proposed to be an optimal BiTE...
Paper Details
Title
Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia
Published Date
Sep 1, 2020
Volume
19
Issue
9
Pages
1875 - 1888
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History